Page 1

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email!

Ariad Pharmaceuticals: PharmaVitae Report Published on June 2012

Report Summary This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug.Gain insight into Ariad Pharmaceuticals' strategic outlookAnalyze company sales forecasts by productAriad's most advanced product candidate is ponatinib, which the company believes has potential in hematological cancers and solid tumors. It is in a pivotal Phase II trial and Ariad plans to file for marketing approval of ponatinib in the US and Europe in the third quarter of 2012.Ariad's second-closest product to approval is AP26112, an investigational dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). These are both targets in non-small cell lung cancer (NSCLC). Depending on the outcome of a Phase I/II trial, Ariad envisions starting a pivotal trial in NSCLC patients in 2013.Benchmark Ariad Pharmaceuticals' performance against key rivals in the prescription pharmaceutical sectorAssess how successful Ariad Pharmaceuticals will be in obtaining marketing approval for its first product

Table of Content ABOUT THIS REPORT'PharmaVitae Explorer database 'Chapter structure - Sales and product analysis - Financial analysis 'Data sourcing - Analyst consensus

EXECUTIVE SUMMARY'Company introduction - Recent developments - Corporate relationships 'Strategic overview 'SWOT analysis - Strengths - Weaknesses - Opportunities - Threats

SALES AND PRODUCT ANALYSIS'Sales overview 'Product analysis - Product sales 'Ponatinib - Chronic myeloid leukemia - Acute lymphoblastic leukemia - Current treatments: marketed drugs for CML do not have activity against the T315I mutation - Current treatments: first-line treatment of ALL consists of combination chemotherapy regimens - Clinical trials

Ariad Pharmaceuticals: PharmaVitae Report (From Issuu)

Page 1/4


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! - Factors affecting ponatinib approval and use - Key forecasting assumptions 'Other products - Ridaforolimus

FINANCIAL ANALYSIS'Financial performance overview - Operating costs and profit analysis, 2005'11 - Operating costs and profit analysis, 2011'17

APPENDIX'References - Datamonitor reports 'Exchange rates

TABLES'Table: Ariad Pharmaceuticals product portfolio overview ($m), 2012'17 'Table: Ariad Pharmaceuticals' clinical trial program includes one pivotal Phase II trial and a planned Phase III trial 'Table: Phase II PACE trial data with ponatinib 'Table: Ponatinib US sales forecast model 'Table: Ponatinib EU sales forecast model 'Table: Ariad operating revenue/cost analysis ($m), 2005'11 'Table: Ariad operating revenue/cost analysis ($m), 2011'17 'Table: Exchange rates, 2011

FIGURES'Figure: PharmaVitae Explorer 'Figure: Ariad prescription pharmaceutical performance, sales ($m) and growth rate (%), 2012'17 'Figure: Ariad Pharmaceuticals key product sales ($m), 2012'17 'Figure: Ariad Pharmaceuticals operating/cost performance ($m), 2005'17

Companies mentioned Amlin plc, Hutchison 3G UK Limited

Ariad Pharmaceuticals: PharmaVitae Report (From Issuu)

Page 2/4


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: ƒ ƒ

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information Please verify that the product information is correct and select the format(s) you require. Ariad Pharmaceuticals: PharmaVitae Report

Product Formats Please select the product formats and the quantity you require.

1 User License--USD 5 700.00

Quantity: _____

Contact Information Please enter all the information below in BLOCK CAPITALS

Title:

Mr

Mrs

Dr

Miss

Ms

Prof

First Name:

_____________________________ Last Name: __________________________________

Email Address:

__________________________________________________________________________

Job Title:

__________________________________________________________________________

Organization:

__________________________________________________________________________

Address:

__________________________________________________________________________

City:

__________________________________________________________________________

Postal / Zip Code:

__________________________________________________________________________

Country:

__________________________________________________________________________

Phone Number:

__________________________________________________________________________

Fax Number:

__________________________________________________________________________

Ariad Pharmaceuticals: PharmaVitae Report (From Issuu)

Page 3/4


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________

Expiry Date

__________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms

Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56

ƒ ƒ

Ariad Pharmaceuticals: PharmaVitae Report (From Issuu)

Asia, Oceania and America : + 1 (805) 617 17 93

Page 4/4

Ariad Pharmaceuticals: PharmaVitae Report  

This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the com...

Read more
Read more
Similar to
Popular now
Just for you